EUVIMEDEUVIMED entdecken
Multizentrische Studie

Performance and Safety of the Extravascular Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy

Konstantinos C Siontis, Francis Murgatroyd, Lucas V A Boersma, Ian Crozier, Jaimie Manlucu, Bradley P Knight, Christophe Leclercq, Ulrika Maria Birgersdotter-Green, Alexander Breitenstein, Henri Roukoz, Laurence M Epstein, Christopher Wiggenhorn und 1 weitere

JACC: Clinical Electrophysiology · 2026-07 · 12 (7) · 1648-1659

DOI: 10.1016/j.jacep.2026.01.052 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Clinical Electrophysiology, 2026-07. Verfasst von Konstantinos C Siontis und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: Siontis.Konstantinos@mayo.edu. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Cardiomyopathy, Hypertrophic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The automatic implantable cardioverter-defibrillator (ICD) is effective in preventing arrhythmic sudden cardiac death in patients with hypertrophic cardiomyopathy (HCM). The extravascular (EV) ICD provides antitachycardia pacing and defibrillation capabilities while avoiding transvenous lead complications. OBJECTIVES: This study sought to evaluate the safety and performance of the novel EV-ICD in patients with HCM. METHODS: This analysis was derived from the Pivotal EV-ICD Study, an international, multicenter, interventional trial evaluating the EV-ICD in patients with guideline-based indications for ICD therapy. Patients were classified according to the presence of a diagnosis of HCM at baseline. The main efficacy endpoint was successful defibrillation testing at implantation. The main safety endpoint was freedom from system- or procedure-related major complications through 3 years of follow-up. RESULTS: A total of 316 patients (mean age 53.8 ± 13.1 years, 25% female, 41 [13%] with HCM) underwent attempted EV-ICD placement. The implantation success rate was 92.7% in HCM patients and 94.9% in non-HCM patients (P = 0.47). Defibrillation testing was successful in 100% and 98.5% of HCM and non-HCM patients, respectively (P = 1.00). During a mean follow-up of 30.6 ± 8.5 months, 1 (2.6%) HCM patient received appropriate ICD therapy (shock for ventricular fibrillation), compared with 23 (8.8%) non-HCM patients (log-rank P = 0.20). Inappropriate ICD therapies occurred in 7 (18.4%) HCM and 41 (15.7%) non-HCM patients (log-rank P = 0.80). System- and procedure-related major complications occurred in 12.2% of HCM and 8.7% of non-HCM patients (log-rank P = 0.44). CONCLUSIONS: In patients with HCM, the EV-ICD demonstrated high defibrillation success and a safety profile similar to what was observed in non-HCM patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Defibrillators, ImplantableCardiomyopathy, HypertrophicHumansFemaleMiddle AgedMaleAdultAgedDeath, Sudden, CardiacTreatment Outcome

Stichwörter der Autor:innen

extravascularhypertrophic cardiomyopathyimplantable cardioverter-defibrillatorventricular tachycardia

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: Siontis.Konstantinos@mayo.edu.
  • King's College Hospital, London, United Kingdom.
  • Cardiology Department of St Antonius Hospital Nieuwegein, Nieuwegein, the Netherlands; Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • Christchurch Hospital, Christchurch, New Zealand.
  • London Health Sciences Centre, Ontario, Canada.
  • Northwestern University, Evanston, Illinois, USA.

Zitieren

APA

Siontis, K. C., Murgatroyd, F., Boersma, L. V. A., Crozier, I., Manlucu, J., Knight, B. P., Leclercq, C., Birgersdotter-Green, U. M., Breitenstein, A., Roukoz, H., Epstein, L. M., Wiggenhorn, C., & Friedman, P. A. (2026). Performance and Safety of the Extravascular Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy. JACC: Clinical Electrophysiology, 12(7), 1648-1659. https://doi.org/10.1016/j.jacep.2026.01.052

Vancouver

Siontis KC, Murgatroyd F, Boersma LVA, Crozier I, Manlucu J, Knight BP, et al. Performance and Safety of the Extravascular Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy. JACC: Clinical Electrophysiology. 2026;12(7):1648-1659. doi:10.1016/j.jacep.2026.01.052

BibTeX
@article{Siontis2026,
  author = {Siontis, Konstantinos C and Murgatroyd, Francis and Boersma, Lucas V A and Crozier, Ian and Manlucu, Jaimie and Knight, Bradley P and Leclercq, Christophe and Birgersdotter-Green, Ulrika Maria and Breitenstein, Alexander and Roukoz, Henri and Epstein, Laurence M and Wiggenhorn, Christopher and Friedman, Paul A},
  title = {Performance and Safety of the Extravascular Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy},
  journal = {JACC: Clinical Electrophysiology},
  year = {2026},
  volume = {12},
  number = {7},
  pages = {1648--1659},
  doi = {10.1016/j.jacep.2026.01.052}
}
Kostenlos starten →